메뉴 건너뛰기




Volumn 77, Issue 1, 2003, Pages 799-803

Overcoming immunity to a viral vaccine by DNA priming before vector boosting

Author keywords

[No Author keywords available]

Indexed keywords

PRIMER DNA; VIRUS GLYCOPROTEIN; VIRUS VACCINE; VIRUS VECTOR;

EID: 0037213293     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.1.799-803.2003     Document Type: Article
Times cited : (192)

References (30)
  • 5
    • 0033551132 scopus 로고    scopus 로고
    • Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity
    • Belyakov, I. M., B. Moss, W. Strober, and J. A. Berzofsky. 1999. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl. Acad. Sci. USA 96:4512-4517.
    • (1999) Proc. Natl. Acad. Sci. USA , vol.96 , pp. 4512-4517
    • Belyakov, I.M.1    Moss, B.2    Strober, W.3    Berzofsky, J.A.4
  • 7
    • 0014632609 scopus 로고
    • Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome
    • Brandt, C. D., H. W. Kim, A. J. Vargosko, B. C. Jeffries, J. O. Arrobio, B. Rindge, R. H. Parrott, and R. M. Chanock. 1969. Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome. Am. J. Epidemiol. 90:484-500.
    • (1969) Am. J. Epidemiol. , vol.90 , pp. 484-500
    • Brandt, C.D.1    Kim, H.W.2    Vargosko, A.J.3    Jeffries, B.C.4    Arrobio, J.O.5    Rindge, B.6    Parrott, R.H.7    Chanock, R.M.8
  • 9
    • 85025432190 scopus 로고    scopus 로고
    • Generation of recombinant vaccinia viruses
    • F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.). John Wiley & Sons, Inc., New York, N.Y.
    • Earl, P. L., B. Moss, L. S. Wyatt, and M. W. Carroll. 1998. Generation of recombinant vaccinia viruses, p. 16.17.1-16.17.19. In F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current Protocols in Molecular Biology. John Wiley & Sons, Inc., New York, N.Y.
    • (1998) Current Protocols in Molecular Biology , pp. 16171-161719
    • Earl, P.L.1    Moss, B.2    Wyatt, L.S.3    Carroll, M.W.4
  • 12
    • 0034046182 scopus 로고    scopus 로고
    • DNA vaccines: Immunology, application, and optimization
    • Gurunathan, S., D. M. Klinman, and R. A. Seder. 2000. DNA vaccines: Immunology, application, and optimization. Annu. Rev. Immunol. 18:927-974.
    • (2000) Annu. Rev. Immunol. , vol.18 , pp. 927-974
    • Gurunathan, S.1    Klinman, D.M.2    Seder, R.A.3
  • 13
    • 0000089873 scopus 로고    scopus 로고
    • Adenoviruses
    • D. M. Knipe and P. M. Howley (ed.). Lippincott, Williams & Wilkins, Philadelphia, Pa
    • Horwitz, M. S. 2001. Adenoviruses, p. 2301-2326. In D. M. Knipe and P. M. Howley (ed.), Fields Virology, 4th Ed. Lippincott, Williams & Wilkins, Philadelphia, Pa.
    • (2001) Fields Virology, 4th Ed. , pp. 2301-2326
    • Horwitz, M.S.1
  • 14
    • 0012075064 scopus 로고
    • A study of illness in a group of Cleveland families. X. The occurrence of adenovirus infections
    • Jordan, W. S., G. F. Badger, C. Curtiss, J. H. Dingle, H. S. Ginsberg, and E. Gold. 1956. A study of illness in a group of Cleveland families. X. The occurrence of adenovirus infections. Am. J. Hyg. 64:336-348.
    • (1956) Am. J. Hyg. , vol.64 , pp. 336-348
    • Jordan, W.S.1    Badger, G.F.2    Curtiss, C.3    Dingle, J.H.4    Ginsberg, H.S.5    Gold, E.6
  • 15
    • 0031772993 scopus 로고    scopus 로고
    • Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
    • Kent, S. J., A. Zhao, S. J. Best, J. D. Chandler, D. B. Boyle, and I. A. Ramshaw. 1998. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72:10180-10188.
    • (1998) J. Virol. , vol.72 , pp. 10180-10188
    • Kent, S.J.1    Zhao, A.2    Best, S.J.3    Chandler, J.D.4    Boyle, D.B.5    Ramshaw, I.A.6
  • 16
    • 0033989650 scopus 로고    scopus 로고
    • Canine adenovirus vectors: An alternative for adenovirus-mediated gene transfer
    • Kremer, E. J., S. Boutin, M. Chillon, and O. Danos. 2000. Canine adenovirus vectors: An alternative for adenovirus-mediated gene transfer. J. Virol. 74:505-512.
    • (2000) J. Virol. , vol.74 , pp. 505-512
    • Kremer, E.J.1    Boutin, S.2    Chillon, M.3    Danos, O.4
  • 18
    • 0029976870 scopus 로고    scopus 로고
    • Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety
    • Moss, B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA 93:11341-11348
    • (1996) Proc. Natl. Acad. Sci. USA , vol.93 , pp. 11341-11348
    • Moss, B.1
  • 19
    • 0035912191 scopus 로고    scopus 로고
    • Challenges and opportunities for development of an AIDS vaccine
    • Nabel, G. J. 2001. Challenges and opportunities for development of an AIDS vaccine. Nature 410:1002-1007.
    • (2001) Nature , vol.410 , pp. 1002-1007
    • Nabel, G.J.1
  • 20
    • 0029957222 scopus 로고    scopus 로고
    • Applications of pox virus vectors to vaccination: An update
    • Paoletti, E. 1996. Applications of pox virus vectors to vaccination: An update. Proc. Natl. Acad. Sci. USA 93:11349-11353.
    • (1996) Proc. Natl. Acad. Sci. USA , vol.93 , pp. 11349-11353
    • Paoletti, E.1
  • 21
    • 9844239902 scopus 로고    scopus 로고
    • DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors
    • Ramsay, A. J., K. H. Leong, and I. A. Ramshaw. 1997. DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors. Immunol. Cell Biol. 75:382-388.
    • (1997) Immunol. Cell Biol. , vol.75 , pp. 382-388
    • Ramsay, A.J.1    Leong, K.H.2    Ramshaw, I.A.3
  • 22
    • 0023937721 scopus 로고
    • Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: Long-term protection and effect of revaccination
    • Rooney, J. F., C. Wohlenberg, K. J. Cremer, B. Moss, and A. L. Notkins. 1988, Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: Long-term protection and effect of revaccination. J. Virol. 62:1530-1534.
    • (1988) J. Virol , vol.62 , pp. 1530-1534
    • Rooney, J.F.1    Wohlenberg, C.2    Cremer, K.J.3    Moss, B.4    Notkins, A.L.5
  • 24
    • 0023235389 scopus 로고
    • Antibody response to enteric adenovirus types 40 and 41 in sera from people in various age groups
    • Shinozaki, T., K. Araki, H. Ushijima, and R. Fujii. 1987. Antibody response to enteric adenovirus types 40 and 41 in sera from people in various age groups. J. Clin. Microbiol. 25:1679-1682.
    • (1987) J. Clin. Microbiol. , vol.25 , pp. 1679-1682
    • Shinozaki, T.1    Araki, K.2    Ushijima, H.3    Fujii, R.4
  • 26
    • 0034735774 scopus 로고    scopus 로고
    • Development of a preventive vaccine for Ebola virus infection in primates
    • Sullivan, N. J., A. Sanchez, P. E. Rollin, Z.-Y. Yang, and G. J. Nabel. 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605-609.
    • (2000) Nature , vol.408 , pp. 605-609
    • Sullivan, N.J.1    Sanchez, A.2    Rollin, P.E.3    Yang, Z.-Y.4    Nabel, G.J.5
  • 27
    • 0031764996 scopus 로고    scopus 로고
    • Canarypox virus-based vaccines: Prime-boost strategies to induce cell-mediated and humoral immunity against HIV
    • Tartaglia, J., J. L. Excler, R. El Habib, K. Limbach, B. Meignier, S. Plotkin, and M. Klein. 1998. Canarypox virus-based vaccines: Prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res. Hum. Retrovir. 14(Suppl. 3):S291-S298.
    • (1998) AIDS Res. Hum. Retrovir. , vol.14 , Issue.SUPPL. 3
    • Tartaglia, J.1    Excler, J.L.2    El Habib, R.3    Limbach, K.4    Meignier, B.5    Plotkin, S.6    Klein, M.7
  • 28
    • 0036187846 scopus 로고    scopus 로고
    • Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product
    • Xiang, Z., G. Gao, A. Reyes-Sandoval, C. J. Cohen, Y. Li, J. M. Bergelson, J. M. Wilson, and H. C. Ertl. 2002. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 76:2667-2675.
    • (2002) J. Virol. , vol.76 , pp. 2667-2675
    • Xiang, Z.1    Gao, G.2    Reyes-Sandoval, A.3    Cohen, C.J.4    Li, Y.5    Bergelson, J.M.6    Wilson, J.M.7    Ertl, H.C.8
  • 30
    • 0033831191 scopus 로고    scopus 로고
    • Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury
    • Yang, Z.-Y., H. J. Duckers, N. J. Sullivan, A. Sanchez, E. G. Nabel, and G. J. Nabel. 2000. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 6:886-889.
    • (2000) Nat. Med. , vol.6 , pp. 886-889
    • Yang, Z.-Y.1    Duckers, H.J.2    Sullivan, N.J.3    Sanchez, A.4    Nabel, E.G.5    Nabel, G.J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.